4.94
21.08%
+0.86
ZyVersa Therapeutics Inc stock is currently priced at $4.94, with a 24-hour trading volume of 400.53K.
It has seen a +21.08% increased in the last 24 hours and a -6.62% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.11 pivot point. If it approaches the $4.67 resistance level, significant changes may occur.
Previous Close:
$4.08
Open:
$3.95
24h Volume:
400.53K
Market Cap:
$4.12M
Revenue:
-
Net Income/Loss:
$-98.30M
P/E Ratio:
-0.6852
EPS:
-7.2097
Net Cash Flow:
$-8.72M
1W Performance:
+14.62%
1M Performance:
-6.62%
6M Performance:
+7,500%
1Y Performance:
+1,250%
ZyVersa Therapeutics Inc Stock (ZVSA) Company Profile
Name
ZyVersa Therapeutics Inc
Sector
Industry
Phone
754 231 1688
Address
2200 N. Commerce Parkway, Suite 208, Weston
ZyVersa Therapeutics Inc Stock (ZVSA) Latest News
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Price Up 21.1% - Defense World
Defense World
Analytical Overview: ZyVersa Therapeutics Inc (ZVSA)'s Ratios Tell a Financial Story – DWinneX - The Dwinnex
The Dwinnex
Peering Into ZyVersa Therapeutics's Recent Short Interest - Investing.com UK
Investing.com UK
ZyVersa Therapeutics reports Q1 EPS ($4.53) vs. ($135.88) last year - TipRanks.com - TipRanks
TipRanks
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
GlobeNewswire
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
ZyVersa Therapeutics Inc Stock (ZVSA) Financials Data
ZyVersa Therapeutics Inc (ZVSA) Net Income 2024
ZVSA net income (TTM) was -$98.30 million for the quarter ending December 31, 2023, a -599.75% decrease year-over-year.
ZyVersa Therapeutics Inc (ZVSA) Cash Flow 2024
ZVSA recorded a free cash flow (TTM) of -$8.72 million for the quarter ending December 31, 2023, a -483.49% decrease year-over-year.
ZyVersa Therapeutics Inc (ZVSA) Earnings per Share 2024
ZVSA earnings per share (TTM) was -$194.32 for the quarter ending December 31, 2023, a -148.47% decline year-over-year.
About ZyVersa Therapeutics Inc
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Cap:
|
Volume (24h):